Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general …

V Furer, T Eviatar, D Zisman, H Peleg… - Annals of the …, 2021 - ard.bmj.com
V Furer, T Eviatar, D Zisman, H Peleg, D Paran, D Levartovsky, M Zisapel, O Elalouf…
Annals of the rheumatic diseases, 2021ard.bmj.com
Introduction Vaccination represents a cornerstone in mastering the COVID-19 pandemic.
Data on immunogenicity and safety of messenger RNA (mRNA) vaccines in patients with
autoimmune inflammatory rheumatic diseases (AIIRD) are limited. Methods A multicentre
observational study evaluated the immunogenicity and safety of the two-dose regimen
BNT162b2 mRNA vaccine in adult patients with AIIRD (n= 686) compared with the general
population (n= 121). Serum IgG antibody levels against SARS-CoV-2 spike S1/S2 proteins …
Introduction
Vaccination represents a cornerstone in mastering the COVID-19 pandemic. Data on immunogenicity and safety of messenger RNA (mRNA) vaccines in patients with autoimmune inflammatory rheumatic diseases (AIIRD) are limited.
Methods
A multicentre observational study evaluated the immunogenicity and safety of the two-dose regimen BNT162b2 mRNA vaccine in adult patients with AIIRD (n=686) compared with the general population (n=121). Serum IgG antibody levels against SARS-CoV-2 spike S1/S2 proteins were measured 2–6 weeks after the second vaccine dose. Seropositivity was defined as IgG ≥15 binding antibody units (BAU)/mL. Vaccination efficacy, safety, and disease activity were assessed within 6 weeks after the second vaccine dose.
Results
Following vaccination, the seropositivity rate and S1/S2 IgG levels were significantly lower among patients with AIIRD versus controls (86% (n=590) vs 100%, p<0.0001 and 132.9±91.7 vs 218.6±82.06 BAU/mL, p<0.0001, respectively). Risk factors for reduced immunogenicity included older age and treatment with glucocorticoids, rituximab, mycophenolate mofetil (MMF), and abatacept. Rituximab was the main cause of a seronegative response (39% seropositivity). There were no postvaccination symptomatic cases of COVID-19 among patients with AIIRD and one mild case in the control group. Major adverse events in patients with AIIRD included death (n=2) several weeks after the second vaccine dose, non-disseminated herpes zoster (n=6), uveitis (n=2), and pericarditis (n=1). Postvaccination disease activity remained stable in the majority of patients.
Conclusion
mRNA BNTb262 vaccine was immunogenic in the majority of patients with AIIRD, with an acceptable safety profile. Treatment with glucocorticoids, rituximab, MMF, and abatacept was associated with a significantly reduced BNT162b2-induced immunogenicity.
ard.bmj.com